Drugs / Domvanalimab
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04656535 | Apr 2021 → Mar 2026 overdue | glioblastoma | Yale University | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03628677 | Sep 2018 → Jan 2025 | cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05419479 | Nov 2022 → May 2026 | pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma | James Cleary, MD, PhD | Suspended | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07134556 | Apr 2026 → May 2028 | triple-negative breast carcinoma | MedSIR | Withdrawn | No outcome recorded |
| Phase 2 | NCT07337447 | Apr 2026 → Apr 2029 expected | neuroendocrine carcinoma | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07283848 | Feb → Dec 2026 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06790706 | Oct 2025 → Nov 2028 expected | carcinoid tumor, digestive system neuroendocrine neoplasm, gestational trophoblastic neoplasm, peritoneal mesothelioma +2 | Hospices Civils de Lyon | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06250036 | Feb 2025 → Mar 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT06727565 | Feb 2025 → Aug 2026 overdue | head and neck squamous cell carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06133517 | Jan 2025 → Jan 2030 expected | infiltrating bladder urothelial carcinoma | Fundación para el Progreso de la Oncología en Cantabria | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05724563 | Jun 2023 → Dec 2027 expected | cholangiocarcinoma, hepatocellular carcinoma | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05633667 | Mar 2023 → Sep 2029 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05676931 | Feb 2023 → Dec 2027 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05329766 | Jun 2022 → Jan 2027 expected | digestive system cancer | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05130177 | Mar 2022 → Feb 2026 overdue | melanoma | Diwakar Davar | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04791839 | Aug 2021 → Oct 2026 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04736173 | Feb 2021 → May 2027 expected | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262856 | May 2020 → Jul 2025 | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03547973 | Aug 2018 → Apr 2030 expected | urothelial carcinoma | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05568095 | Nov 2022 → Jun 2026 overdue | adenocarcinoma | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05502237 | Oct 2022 → Jun 2028 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05211895 | Feb 2022 → Jul 2028 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04999761 Background | Jun 2021 → May 2026 overdue | alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer +4 | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | Gilead Sciences | Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers gilead.com ↗ |
| 2023-11-06 | Gilead Sciences | Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers gilead.com ↗ |
| 2023-06-03 | Gilead Sciences | Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study gilead.com ↗ |
| 2022-12-19 | Gilead Sciences | Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study gilead.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Domvanalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05502237 ↗ |
| Known as | AB 154 | “This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab...” NCT05211895 ↗3“Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.” NCT04656535 ↗ “* Domvanalimab (also known as AB154)” NCT05419479 ↗ |
| Known as | DOM | “Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy” NCT05502237 ↗1“Drug: Domvanalimab (DOM)” NCT07134556 ↗ |
| Action | Inhibit | “TIGIT inhibitor domvanalimab” NCT05130177 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT04262856 ↗ |
| Route | Intravenous | “Administered intravenously” NCT03547973 ↗ |
| Target | TIGIT | “targeting human TIGIT” NCT04262856 ↗ |